These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 34414692)

  • 1. An exploratory first-in-man study to investigate the pharmacokinetics and safety of liposomal dexamethasone at a 2- and 1-week interval in patients with metastatic castration resistant prostate cancer.
    Vrouwe JPM; Kamerling IMC; van Esdonk MJ; Metselaar JM; Stuurman FE; van der Pluijm G; Burggraaf J; Osanto S
    Pharmacol Res Perspect; 2021 Oct; 9(5):e00845. PubMed ID: 34414692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patients.
    Di Desidero T; Derosa L; Galli L; Orlandi P; Fontana A; Fioravanti A; Marconcini R; Giorgi M; Campi B; Saba A; Lucchesi S; Felipetto R; Danesi R; Francia G; Allegrini G; Falcone A; Bocci G
    Invest New Drugs; 2016 Dec; 34(6):760-770. PubMed ID: 27557783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial.
    Fizazi K; Massard C; Bono P; Jones R; Kataja V; James N; Garcia JA; Protheroe A; Tammela TL; Elliott T; Mattila L; Aspegren J; Vuorela A; Langmuir P; Mustonen M;
    Lancet Oncol; 2014 Aug; 15(9):975-85. PubMed ID: 24974051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of metronomic oral cyclophosphamide with low dose dexamethasone and celecoxib in metastatic castration-resistant prostate cancer.
    Jeong Y; Lee JL
    Asia Pac J Clin Oncol; 2017 Jun; 13(3):204-211. PubMed ID: 27521286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment outcome of docetaxel plus prednisolone for metastatic castration-resistant prostate cancer in Korea.
    Cho IC; Joung JY; Seo HK; Chung J; Park WS; Lee KH
    J Cancer Res Ther; 2014; 10(2):251-7. PubMed ID: 25022374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
    Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
    Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Docetaxel-based chemotherapy combined with dexamethasone 1 mg daily oral administration for castration-resistant prostate cancer: Long-term outcomes.
    Tanaka N; Nishimura K; Okajima E; Ina K; Ogawa O; Nagata H; Akakura K; Fujimoto K; Gotoh M; Teramukai S; Hirao Y
    Int J Urol; 2019 Aug; 26(8):797-803. PubMed ID: 31055879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Paclitaxel liposome for the treatment of castration-resistant prostate cancer].
    Zhu SS; Zhang FY; Xue S; Sun XQ
    Zhonghua Nan Ke Xue; 2020 Sep; 26(9):788-792. PubMed ID: 33377700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of short-term dexamethasone on the efficacy of
    Derlin T; Sommerlath Sohns JM; Schmuck S; Henkenberens C; von Klot CAJ; Ross TL; Bengel FM
    Prostate; 2020 May; 80(8):619-631. PubMed ID: 32187729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PSA response to cabazitaxel is associated with improved progression-free survival in metastatic castration-resistant prostate cancer: the non-interventional QoLiTime study.
    Hammerer P; Al-Batran SE; Windemuth-Kieselbach C; Keller M; Hofheinz RD
    World J Urol; 2018 Mar; 36(3):375-381. PubMed ID: 29305637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer.
    Milowsky MI; Galsky MD; Morris MJ; Crona DJ; George DJ; Dreicer R; Tse K; Petruck J; Webb IJ; Bander NH; Nanus DM; Scher HI
    Urol Oncol; 2016 Dec; 34(12):530.e15-530.e21. PubMed ID: 27765518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302.
    Saad F; Shore N; Van Poppel H; Rathkopf DE; Smith MR; de Bono JS; Logothetis CJ; de Souza P; Fizazi K; Mulders PF; Mainwaring P; Hainsworth JD; Beer TM; North S; Fradet Y; Griffin TA; De Porre P; Londhe A; Kheoh T; Small EJ; Scher HI; Molina A; Ryan CJ
    Eur Urol; 2015 Oct; 68(4):570-7. PubMed ID: 25985882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH study).
    Romero-Laorden N; Lozano R; Jayaram A; López-Campos F; Saez MI; Montesa A; Gutierrez-Pecharoman A; Villatoro R; Herrera B; Correa R; Rosero A; Pacheco MI; Garcés T; Cendón Y; Nombela MP; Van de Poll F; Grau G; Rivera L; López PP; Cruz JJ; Lorente D; Attard G; Castro E; Olmos D
    Br J Cancer; 2018 Oct; 119(9):1052-1059. PubMed ID: 30131546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enzalutamide in Combination with Abiraterone Acetate in Bone Metastatic Castration-resistant Prostate Cancer Patients.
    Efstathiou E; Titus M; Wen S; Troncoso P; Hoang A; Corn P; Prokhorova I; Araujo J; Dmuchowski C; Melhem-Bertrandt A; Patil S; Logothetis CJ
    Eur Urol Oncol; 2020 Feb; 3(1):119-127. PubMed ID: 31412017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liposomal delivery of dexamethasone attenuates prostate cancer bone metastatic tumor growth in vivo.
    Kroon J; Buijs JT; van der Horst G; Cheung H; van der Mark M; van Bloois L; Rizzo LY; Lammers T; Pelger RC; Storm G; van der Pluijm G; Metselaar JM
    Prostate; 2015 Jun; 75(8):815-24. PubMed ID: 25663076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sunitinib maintenance therapy after response to docetaxel in metastatic castration resistant prostate cancer (mCRPC).
    Parimi S; Eliasziw M; North S; Trudeau M; Winquist E; Chi KN; Ruether D; Cheng T; Eigl BJ
    Invest New Drugs; 2016 Dec; 34(6):771-776. PubMed ID: 27565809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of
    Yadav MP; Ballal S; Sahoo RK; Tripathi M; Seth A; Bal C
    Theranostics; 2020; 10(20):9364-9377. PubMed ID: 32802197
    [No Abstract]   [Full Text] [Related]  

  • 18. Prostate-Specific Antigen Flare Phenomenon During
    De Vincentis G; Follacchio GA; Frantellizzi V; Liberatore M; Monteleone F; Cortesi E
    Clin Genitourin Cancer; 2016 Oct; 14(5):e529-e533. PubMed ID: 27212044
    [No Abstract]   [Full Text] [Related]  

  • 19. Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study.
    Yu EY; Kolinsky MP; Berry WR; Retz M; Mourey L; Piulats JM; Appleman LJ; Romano E; Gravis G; Gurney H; Bögemann M; Emmenegger U; Joshua AM; Linch M; Sridhar S; Conter HJ; Laguerre B; Massard C; Li XT; Schloss C; Poehlein CH; de Bono JS
    Eur Urol; 2022 Jul; 82(1):22-30. PubMed ID: 35397952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Weekly versus 3-weekly cabazitaxel for the treatment of castration-resistant prostate cancer: A randomised phase II trial (ConCab).
    Yachnin J; Gilje B; Thon K; Johansson H; Brandberg Y; Panaretakis T; Ullén A
    Eur J Cancer; 2018 Jul; 97():33-40. PubMed ID: 29685343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.